Lineage Cell Therapeutics (LCTX) Q4 2022 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2022 earnings summary
9 Nov, 2026Executive summary
2022 focused on clinical and regulatory execution, pipeline expansion, and the Roche/Genentech alliance; the inaugural sustainability report also formalized ESG oversight and priorities.
The platform develops allogeneic cell therapies intended to replace or support absent or dysfunctional cells and restore function in patients.
Financial highlights
OpRegen partnership value is stated as $670M, including a $50M upfront payment received in Jan. 2022, $620M in eligible milestones, and double-digit royalties on sales.
Outlook and guidance
2023 objectives are to advance allogeneic cell therapy programs, invest responsibly in the cell transplant platform, and support new and existing collaborations.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Lineage Cell Therapeutics
- HUNT1 joins the pipeline as warrant gains lift Q3 earnings and runway extends into Q2 2028.LCTX
Q3 2026 - Returned to profitability in Q2 2026 with strong clinical progress and cash runway into Q3 2028.LCTXQ2 2026
- COR1 advances scalable, high-quality cell therapy for corneal disease with animal data expected soon.LCTXStudy update
- OpRegen's cell therapy for dry AMD shows durable vision gains and global expansion with Roche.LCTXH.C. Wainwright 4th Annual Ophthalmology Virtual Conference
- Lead cell therapy programs in dry AMD and spinal cord injury show durable clinical benefits.LCTXCorporate presentation
- Q1 2026 revenue up 15% to $1.7M, $53.4M cash, pipeline and manufacturing milestones achieved.LCTXQ1 2026
- Votes will be held on director elections, auditor ratification, and executive pay approval.LCTXProxy filing
- Director elections, auditor ratification, and executive pay approval headline the 2026 meeting.LCTXProxy filing
- Durable clinical gains, improved financials, and manufacturing strength drive program momentum.LCTXQ4 2024